Skip navigation
Watchlist Sponsored By :


Current DateTime: 03:28:46 10 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 03:28:46 10 Nov 2009
LinksList Documentid: 33793611

Current DateTime: 03:28:47 10 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Dendreon Shares Continue Upswing Despite Analyst Warning
By: AP | 09 Apr 2007 | 10:34 AM ET
Text Size

An analyst sounded a warning note on shares of biotechnology company Dendreon on Monday, which have more than tripled in value since March 30, but the stock continued to rise.

A Food and Drug Administration panel endorsed Provenge, a prostate cancer vaccine, on March 30, saying there was evidence the drug could be an effective cancer fighter. The agency usually follows panel recommendations in evaluating new drug applications.

(DNDN)
Loading...       (%)

Brean Murray Carret & Co. analyst Jonathan Aschoff said the FDA would set a "dangerous double standard" by approving Provenge, which did not meet its primary goal in two phase III trials. He said the FDA rejected Pharmacyclics' new drug application for Xcytrin for not reaching its goals, but agreed to review the Provenge application.

Aschoff has "Sell" rating and a price target of $1.50 for shares of Seattle-based Dendreon, implying the stock will lose 91.7 percent of its value in the next year.

Five of the nine analysts reporting to Thomson Financial rate Dendreon stock at "Buy" or the equivalent. Two analysts rate it at "Neutral"-equivalent and two at "Sell"-equivalent.

Dendreon were up [DNDN  Loading...      ()   ] on the Nasdaq Stock Market. The stock hit a new all-time high of $21 shortly after the open Monday.

© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
  • Jim Cramer
  • Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
  • On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
  • Gavel
  • Software, biotech firms, even banks are watching a particular Supreme Court argument today.
  • From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
  • The health care reform bill that passed the House on Saturday will have a much harder time in the Senate.
ADD COMMENTS
Remaining characters


Current DateTime: 01:38:20 10 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:00:35 10 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:17:18 10 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:00:36 10 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters